We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Cites Hawaii PET Drugmaker for Quality Violations
FDA Cites Hawaii PET Drugmaker for Quality Violations
Issues ranging from unqualified personnel to inadequate recordkeeping netted Honolulu, Hawaii-based positron emission tomography (PET) drugmaker Hamamatsu/Queens PET Imaging Center a Form 483 from the FDA.